Amphastar Pharmaceuticals, Inc. (AMPH) FY2026 Q2 P&L / Income Statement

Amphastar Pharmaceuticals, Inc. (AMPH) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Segments by Subsegments. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

183,903,000 US dollars

Cost of revenues

90,433,000 US dollars

Gross profit

93,470,000 US dollars

Total operating expenses

53,741,000 US dollars

Income from operations

39,729,000 US dollars

Total non-operating income (expenses), net

negative 1,185,000 US dollars

Income before income taxes

38,544,000 US dollars

Income tax provision

8,196,000 US dollars

Net income

30,348,000 US dollars

Finished Pharmaceutical Products Segment - BAQSIMI

45,503,000 US dollars

Finished Pharmaceutical Products Segment - Epinephrine

15,854,000 US dollars

Finished Pharmaceutical Products Segment - Glucagon

11,905,000 US dollars

Finished Pharmaceutical Products Segment - Ipratropium Bromide

8,411,000 US dollars

Finished Pharmaceutical Products Segment - Lidocaine

15,039,000 US dollars

Finished Pharmaceutical Products Segment - Other Products

66,187,000 US dollars

Finished Pharmaceutical Products Segment - Primatene MIST

21,004,000 US dollars

Research and development

22,164,000 US dollars

General and administrative

18,242,000 US dollars

Selling, distribution, and marketing

13,335,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.